Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, Mark McKeage, Dong Wang Kim, Ullas Batra, Gloria Borra, Sergey Orlov, Sang We Kim, Sarayut L. Geater, Pieter E. Postmus, Scott A. Laurie, Keunchil Park, Cheng Ta Yang, Andrea Ardizzoni, Anna C. Bettini, Gilberto de Castro, Flavia Kiertsman, Zhe Chen, Yvonne Y. LauKalyanee Viraswami-Appanna, Vanessa Q. Passos, Rafal Dziadziuszko

Research output: Contribution to journalArticle

13 Citations (Scopus)

Fingerprint Dive into the research topics of 'Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences